OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Effectiveness of bimekizumab for genital, nail, and scalp lesions with psoriasis: A 24‐week real‐world study
Teppei Hagino, Marina Onda, Hidehisa Saeki, et al.
The Journal of Dermatology (2024)
Closed Access | Times Cited: 8
Teppei Hagino, Marina Onda, Hidehisa Saeki, et al.
The Journal of Dermatology (2024)
Closed Access | Times Cited: 8
Showing 8 citing articles:
Bimekizumab Treatment for Scalp Psoriasis: A 52‐Week, Real‐World, Retrospective Study
Irene Stefanaki, Ioannis‐Alexios Koumprentziotis, Natalia Rompoti, et al.
International Journal of Dermatology (2025)
Closed Access | Times Cited: 1
Irene Stefanaki, Ioannis‐Alexios Koumprentziotis, Natalia Rompoti, et al.
International Journal of Dermatology (2025)
Closed Access | Times Cited: 1
Long‐term real‐world effectiveness of deucravacitinib in psoriasis: A 52‐week prospective study stratified by prior apremilast or biologic therapy
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
The Journal of Dermatology (2025)
Open Access
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
The Journal of Dermatology (2025)
Open Access
Psoriasis increases the risk of Sjögren’s syndrome: evidence from a propensity score-matched cohort study and transcriptomic analysis
Zijian Kang, Yu Du, Ran Cui, et al.
BMC Medicine (2025) Vol. 23, Iss. 1
Open Access
Zijian Kang, Yu Du, Ran Cui, et al.
BMC Medicine (2025) Vol. 23, Iss. 1
Open Access
Real‐world 52‐week effectiveness of deucravacitinib in psoriasis: A stratified analysis by age and body mass index
Teppei Hagino, Marina Onda, Hidehisa Saeki, et al.
The Journal of Dermatology (2025)
Closed Access
Teppei Hagino, Marina Onda, Hidehisa Saeki, et al.
The Journal of Dermatology (2025)
Closed Access
Long‐term maintenance of responses to bimekizumab treatment in moderate‐to‐severe psoriasis: A real‐world comparison of Q4W versus Q8W dosing or bio‐naïve versus bio‐switched patients
Marina Onda, Teppei Hagino, Hidehisa Saeki, et al.
The Journal of Dermatology (2025)
Open Access
Marina Onda, Teppei Hagino, Hidehisa Saeki, et al.
The Journal of Dermatology (2025)
Open Access
Psychosocial interventions for psoriasis: a Bayesian network meta-analysis
Lingling Lu, Yujuan Xu, Meiling Shi, et al.
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access
Lingling Lu, Yujuan Xu, Meiling Shi, et al.
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access
Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation—IL PSO (Italian Landscape Psoriasis)
Maria Esposito, Paolo Gisondi, Chiara Assorgi, et al.
Clinical Drug Investigation (2025)
Open Access
Maria Esposito, Paolo Gisondi, Chiara Assorgi, et al.
Clinical Drug Investigation (2025)
Open Access
Updates on Psoriasis in Special Areas
Alexandra‐Irina Butacu, Cristian Toma, Iulia-Elena Negulet, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 24, pp. 7549-7549
Open Access | Times Cited: 2
Alexandra‐Irina Butacu, Cristian Toma, Iulia-Elena Negulet, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 24, pp. 7549-7549
Open Access | Times Cited: 2
Bimekizumab for the treatment of genital, scalp, and nail psoriasis: A 52‐week real‐world study
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
The Journal of Dermatology (2024)
Closed Access | Times Cited: 1
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
The Journal of Dermatology (2024)
Closed Access | Times Cited: 1
